skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

12013

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs



Review

(10717) Total Article Views


Authors: Manil Kukar, Olga Petryna, Petros Efthimiou

Published Date September 2009 Volume 2009:3 Pages 443 - 457
DOI: http://dx.doi.org/10.2147/BTT.S6640

Manil Kukar1, Olga Petryna1, Petros Efthimiou2

1Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USA

Abstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the role of cytokines has enabled the development of innovative biological agents in the last 10 years that target specific parts of the immune response. Failure to achieve adequate response with traditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing radiographic deterioration of the affected joints despite seemingly clinical response were essential stimuli for the development of biologics. The current and upcoming biological agents are primarily aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to inflammation. These agents have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. However, use of these agents has also been associated with significant, although rare, adverse events and considerable cost. Therefore, these agents should be used with caution by experienced clinicians. The present work aims to provide a global and updated review of the current and in-development biological DMARDs for the treatment of RA.

Keywords: biological agents, rheumatoid arthritis, immunomodulators, treatment, cytokines




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.

  • Journal Indexing

    See where all the Dove Press journals are indexed.